Apellis Pharmaceuticals, Inc. (APLS)

40.92 -0.02 (-0.05%) USD  |  NASDAQ  |  Apr 22, 10:00
More

Apellis Pharmaceuticals Price Target Std Dev

Price Target Std Dev Chart

View Price Target Std Dev for APLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Price Target Std Dev Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Price Target Std Dev Range, Past 5 Years

View Price Target Std Dev Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price Target Std Dev Benchmarks

View Price Target Std Dev Benchmarks
Start Trial
Biogen, Inc. Upgrade
Eli Lilly & Co. Upgrade
Agios Pharmaceuticals, Inc. Upgrade
Scholar Rock Holding Corp. Upgrade
Kezar Life Sciences, Inc. Upgrade